Cost effectiveness of Daclatasvir/Asunaprevir versus Peginterferon/Ribavirin and protease inhibitors for the treatment of Hepatitis C genotype 1b naive patients in Chile

dc.contributor.authorVargas, Constanza L.
dc.contributor.authorEspinoza SepĂșlveda, Manuel Antonio
dc.contributor.authorGiglio, Andres
dc.contributor.authorSoza, Alejandro
dc.date.accessioned2020-08-21T23:15:58Z
dc.date.available2020-08-21T23:15:58Z
dc.date.issued2015
dc.fuente.origenConveris
dc.identifier.doi10.1371/journal.pone.0141660
dc.identifier.issn1932-6203
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0141660
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/40104
dc.issue.numeroNo. 11
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final16
dc.pagina.inicio1
dc.revistaPLoS ONEes_ES
dc.rightsacceso abierto
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.otherHepatitis Ces_ES
dc.subject.otherHepatitis C - Terapiaes_ES
dc.subject.otherFarmacologĂ­aes_ES
dc.titleCost effectiveness of Daclatasvir/Asunaprevir versus Peginterferon/Ribavirin and protease inhibitors for the treatment of Hepatitis C genotype 1b naive patients in Chilees_ES
dc.typeartĂ­culo
dc.volumenVol. 10
sipa.codpersvinculados10720
sipa.codpersvinculados461
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cost effectiveness of daclatasvir asunaprevir.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format
Description: